Alaunos Therapeutics (TCRT) Set to Release Earnings on Tuesday

Alaunos Therapeutics (NASDAQ:TCRT) is anticipated to issue its Q3 2026 resultson Tuesday, November 17th. Analysts expect Alaunos Therapeutics to announce earnings of ($15.75) per share for the quarter. Parties can find conference call details on the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Friday, November 20, 2026 at 4:00 PM ET.

Alaunos Therapeutics (NASDAQ:TCRT) last posted its earnings results on Friday, August 14th. The company reported ($0.41) EPS for the quarter.

Alaunos Therapeutics Stock Down 4.0%

Shares of Alaunos Therapeutics stock opened at $1.67 on Tuesday. Alaunos Therapeutics has a 52 week low of $0.72 and a 52 week high of $4.50. The business’s fifty day simple moving average is $1.64 and its 200-day simple moving average is $2.30.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings downgraded Alaunos Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, August 17th. One equities research analyst has rated the stock with a Sell rating. According to MarketBeat, the stock has an average rating of “Sell”.

About Alaunos Therapeutics

Alaunos Therapeutics, Inc is a biotechnology company focused on developing genetically engineered T-cell therapies for cancer. The company has concentrated on T-cell receptor (TCR) therapies designed to recognize and attack tumor-specific mutations, with an emphasis on treating solid tumors that can be difficult to address with conventional immunotherapies.

The company’s research platform has included the Sleeping Beauty gene-transfer system, a nonviral technology intended to introduce therapeutic T-cell receptors into a patient’s own T cells.